Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases.
52W Range
30thpctl
Volume
0.24×avg
Market Cap
42.76MUSD
P/E Ratio
-0.9TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Aligos Therapeutics, Inc.
ALGSNASDAQ Global Select·USD·Closed
Aligos Therapeutics, Inc.
ALGSNASDAQ·USD·Closed
$6.91
−2.26%
$6.91
−$0.16 (2.26%)
52W Range
30thpctl
Volume
0.24×avg
Mkt Cap
42.76MUSD
P/E
-0.9TTM
Div Yield
–ann
ALGS: Aligos Therapeutics, Inc. Stock Analysis | finqOS
